Beijing Tiantan Biological Products Corporation Limited Class A

Beijing Tiantan Biological Products Corporation Limited Class A

SSSE:600161
12.02
CNY
-0.11
(-0.91%)
0.48EPS
36.10P/E
24.90BMarket Cap
Apr 27Next Earn
Beijing Tiantan Biological Products Corporation Limited Class A
SSE:600161
(Shanghai Stock Exchange)

Recent

price

12.02

P/E

ratio

36.10

div

yld

0.00%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.67
0.77
0.83
1.01
1.01
0.93
1.17
1.38
1.63
1.83
1.91
2.12
2.14
2.61
3.04
3.11
2.77
Revenue per Share
0.1
0.13
0.17
0.21
0.07
0.01
0.14
0.65
0.28
0.34
0.35
0.39
0.44
0.56
0.78
0.55
0.35
Basic EPS, GAAP
-0.06
-0.2
-0.07
0.01
0.01
0.1
0.12
-0.04
0.21
0.06
0.05
-0.08
-0.11
0.66
-0.12
-0.13
- -
Free Cash Flow per Basic Share
0.04
0.06
0.08
0.06
0.08
0.07
0.06
0.11
0.08
0.03
0.05
0.08
0.08
0.05
0.12
0.25
- -
Dividend per Share
0.58
0.71
0.86
1.07
1.07
1.07
1.3
2.03
1.87
2.18
2.5
4.07
4.45
4.97
5.63
5.93
6
Book Value per Share
0.46
0.6
0.74
0.95
0.96
0.97
1.13
1.85
1.65
1.93
2.22
3.65
3.89
4.35
4.68
4.92
4.95
Tangible Book Value per Share
1,803
1,817
1,811
1,811
1,800
1,748
1,822
1,802
1,797
1,796
1,804
1,940
1,995
1,982
1,986
1,983
2,007
Basic Weighted Avg Shares
1,202
1,394
1,502
1,837
1,827
1,618
2,138
2,483
2,931
3,282
3,446
4,112
4,261
5,180
6,032
6,168
5,555
Sales/Revenue/Turnover
23.41
29.12
31.61
32.6
25.25
22.59
23.7
31.99
29.21
31.34
31.16
28.81
31.28
33.25
41.8
30.68
22.89
Operating Margin (%)
81
87
89
92
111
196
215
169
130
128
133
157
180
268
332
425
- -
Depreciation Expense
175
233
305
372
128
10
257
1,173
509
611
639
760
881
1,110
1,549
1,091
700
Net Income, GAAP
17.38
14.66
16.88
15.6
25.5
41.61
20
10.47
15.21
14.3
14.64
13.88
15.54
16.08
17.08
18.26
21.42
Effective Tax Rate (%)
14.55
16.73
20.3
20.26
7.03
0.62
12.01
47.24
17.38
18.62
18.55
18.48
20.67
21.42
25.68
17.69
12.6
Profit Margin (%)
282
240
-32
100
-471
335
805
3,244
2,951
3,394
3,699
6,736
6,113
6,290
6,602
7,238
7,455
Working Capital
360
708
1,300
1,459
1,044
1,780
1,912
200
231
401
503
384
279
24
45
68
63
LT Debt
1,142
1,446
1,777
2,176
2,218
2,236
2,622
4,450
4,347
5,177
6,031
10,267
11,356
12,754
14,533
15,316
15,545
Total Equity
11.94
11.75
10.87
11.31
4.61
2.28
5.87
27.9
15.37
17.4
14.95
12.02
10.62
12.21
15.31
9.9
- -
Return on Invested Capital (%)
8.46
9.03
8.62
7.85
2.74
-0.5
6.26
20.27
6.12
6.46
5.42
5.14
4.96
5.81
7.23
4.64
- -
Return on Capital (%)
18.87
19.91
21.45
21.38
6.64
0.51
11.99
39.04
14.47
16.72
15.11
12.09
10.46
11.92
14.78
9.54
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
21
84
16
LT Borrowings
- -
- -
- -
LT Finance Leases
71
68
63
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,977
1,977
1,977
Market Capitalization
29,878
22,898
24,895

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
8,353
8,742
8,502
Cash, Cash Equivalents & STI
1,892
2,168
1,901
Accounts Receivable, Net
1,343
1,546
1,477
Inventories
4,148
4,127
4,256
Total Current Liabilities
947
1,252
1,047
Payables & Accruals
- -
- -
- -
ST Debt
21
84
16
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
23.27%
22.5%
5.39%
Free Cash Flow
-179%
-199.99%
7.73%
Net Income, GAAP
287.02%
14.17%
-29.59%
Sales/Revenue/Turnover
14.65%
12.65%
2.26%
Total Cash Common Dividend
33.64%
59.01%
100%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,222
1,619
1,232
1,959
6,032
2025
1,318
1,793
- -
1,703
6,168
2026
1,142
1,454
1,257
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.16
0.21
0.16
0.25
0.78
2025
0.12
0.2
- -
0.14
0.55
2026
0.06
0.09
0.07
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.12
2025
- -
- -
- -
- -
0.25
2026
- -
- -
- -
- -
- -
Business
Beijing Tiantan Biological Products Co., Ltd. specializes in the discovery, production, and distribution of essential biopharmaceutical products across China. The company's portfolio encompasses a wide array of plasma-derived treatments, including human albumin, various immunoglobulins like intravenous, hepatitis B, tetanus, and rabies types, alongside critical coagulation factors such as Factor VIII and prothrombin complex. Additionally, it develops recombinant products and a selection of preventive vaccines. Established in 1998 and based in Beijing, China, the company is recognized as a leader within the Chinese blood product sector, commanding the largest plasma collection volume in the domestic market, reaching 2,415 tons in 2023 and accounting for 20% of the market share. Beijing Tiantan Biological is a subsidiary operating under China National Biotec Group Company Limited, itself a part of Sinopharm, and holds a significant role in national blood product reserves. Recent innovations include the approval of its fourth-generation 10% Intravenous Immunoglobulin, which utilizes a chromatography process, and the marketing authorization for its recombinant human coagulation factor VIII for injection.